Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Takeda President Hasegawa Plans to Complete Integration with Nycomed in 3 Years
November 7, 2011
- Ono: Glactiv, Emend Drive Growth in 1st-Half Sales
November 7, 2011
- Astellas President Hatanaka Says Company Can Continue on Growth Path Through 2014
November 7, 2011
- Kissei: Pharm. Sales Down 0.5%, Profits Up
November 7, 2011
- ASKA: Sales Down 8.4% Due to Rebound from a Spike at Last Fiscal Year End
November 7, 2011
- Breast Cancer Project Selected for Health Science Research Grant: 3-D Matrix
November 7, 2011
- Pharmacies Satisfied, Wholesalers Dissatisfied with Price Negotiations: Yano Research Survey
November 7, 2011
- CMIC: Sales, Profits Up Driven by CRO Business
November 7, 2011
- Kawasumi Lab.: Declines in Sales, Profits
November 7, 2011
- Takara Bio: Research Reagents Drive Growth in Sales, Profits
November 7, 2011
- Sales of Actos Down 22% in 1st Half Due to Bladder Cancer Concerns, Generic Competition: Takeda
November 5, 2011
- Qol Decides to Discontinue “Dispensing Points” in March 2012
November 4, 2011
- Ono President Says Glactiv to “Still Show Advantage of Early Release”
November 4, 2011
- Asahi Kasei Pharma’s Apr-Sep Sales Up 6% Due to Doubled Recomodulin Sales
November 4, 2011
- Once-Yearly Dosing Osteoporosis Agent Starts PIII Study: Asahi Kasei Pharma
November 4, 2011
- FDA Assigns Action Date of Jan 25, 2012 for Takeda’s Alogliptin
November 4, 2011
- Sales of Medical & Pharmaceutical Business Increased 2.4% Driven by New Drugs: Teijin
November 4, 2011
- Astellas: Sales, Profits Up in First Half Driven by Vesicare
November 4, 2011
- Eisai Announces Double-digit Declines in 1st-Half Sales, Profits
November 4, 2011
- Kaken: Mainstay Products, Generics Pull Business
November 4, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…